MedTrace Logo

Analgesia Effects of Nalbuphine vs Sulfentanil

NCT02604797 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-11-13

No results posted yet for this study

Summary

Cesarean section may result in great trauma and postoperative pain. Besides incision pain, uterine contraction pain is another source of postoperative pain after cesarean section. In clinical practice, a large amount of uterine contraction agent is routinely applied after cesarean section so as to promote involution of uterus and reduce postoperative hemorrhage, which also causes great uterine contraction pain. Acute pain is the risk factor of chronic pain, and may postpone the recovery from labour and influence the quality of life of parturient. Though various analgesia modules have been attempted, more than 20% parturients still experience severe postoperative pain, and pain management after cesarean section remains a challenge to anesthesiologists.

This study aim to compare the effects of nalbuphine hydrochloride vs sufentanil citrate on patient-controlled intravenous analgesia after cesarean section.

Conditions

  • C.Delivery; Surgery (Previous), Gynecological

Interventions

DRUG

Nalbuphine

patient-controlled intravenous analgesia

DRUG

Sufentanil

patient-controlled intravenous analgesia

DRUG

flurbiprofen axetil

patient-controlled intravenous analgesia

DRUG

ramosetron

patient-controlled intravenous analgesia

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Shaoqiang Huang · Department of Anesthesiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-31
Completion
2018-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02604797 on ClinicalTrials.gov